BrdU Recombinant Mouse Monoclonal Antibody [A9C7-R] - BSA and Azide free
Catalog# HA610183
BrdU Recombinant Mouse Monoclonal Antibody [A9C7-R] - BSA and Azide free
-
IHC-P
-
IF-Tissue
-
IF-Cell
-
FC
-
Species independent
-
HA601311
含抗保成分
-
unconjugated
Overview
Product Name
BrdU Recombinant Mouse Monoclonal Antibody [A9C7-R] - BSA and Azide free
Antibody Type
Recombinant Mouse Monoclonal Antibody
Immunogen
BrdU-OVA
Species Reactivity
Species independent
Validated Applications
IHC-P, IF-Tissue, IF-Cell, FC
Positive Control
BrdU treated mouse embryo tissue, BrdU treated NIH/3T3.
Conjugation
unconjugated
Clone Number
A9C7-R
Product Features
Form
Liquid
Concentration
1mg/ml
Storage Instructions
Store at +4℃ after thawing. Aliquot store at -20℃. Avoid repeated freeze / thaw cycles.
Storage Buffer
1*PBS (pH7.4).
Isotype
IgG1
Purification Method
Protein A affinity purified.
Application Dilution
-
IHC-P
-
1:5,000
-
IF-Tissue
-
1:500
-
IF-Cell
-
1:250
-
FC
-
1:1,000
Target
Function
Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU, BUdR, BrdUrd, broxuridine) is a synthetic nucleoside analogue with a chemical structure similar to thymidine. BrdU is commonly used to study cell proliferation in living tissues and has been studied as a radiosensitizer and diagnostic tool in people with cancer. During S phase of the cell cycle (when DNA replication occurs), BrdU can be incorporated in place of thymidine in newly synthesized DNA molecules of dividing cells. Cells that have recently performed DNA replication or DNA repair can be detected with antibodies specific for BrdU using techniques such as immunohistochemistry or immunofluorescence. BrdU-labelled cells in humans can be detected up to two years after BrdU infusion. Because BrdU can replace thymidine during DNA replication, it can cause mutations, and its use is therefore potentially a health hazard. However, because it is neither radioactive nor myelotoxic at labeling concentrations, it is widely preferred for in vivo studies of cancer cell proliferation. However, at radiosensitizing concentrations, BrdU becomes myelosuppressive, thus limiting its use for radiosensitizing. BrdU differs from thymidine in that BrdU substitutes a bromine atom for thymidine's CH3 group. The Br substitution can be used in X-ray diffraction experiments in crystals containing either DNA or RNA. The Br atom acts as an anomalous scatterer and its larger size will affect the crystal's X-ray diffraction enough to detect isomorphous differences as well. Bromodeoxyuridine releases gene silencing caused by DNA methylation. DNA with BrdU transcribes as usual DNA, with guanine included into RNA as a complement to BrdU. This antibody clone cross-reacts with Edu.
Background References
1. Wang T et al. Unexpected BrdU inhibition on astrocyte-to-neuron conversion. Neural Regen Res. 2022 Jul
2. Yu J et al. BrdU Incorporation Assay to Analyze the Entry into S Phase. Methods Mol Biol. 2022
Subcellular Location
Nucleus.
Synonyms
Bromodeoxyuridine antibody
BUdr antibody
Images
-
Immunohistochemical analysis of paraffin-embedded BrdU treated mouse embryo tissue with Mouse anti-BrdU antibody (HA610183) at 1/5,000 dilution.
The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) (high pressure) for 2 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (HA610183) at 1/5,000 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunofluorescence analysis of paraffin-embedded BrdU treated mouse embryo tissue labeling BrdU with Mouse anti-BrdU antibody (HA610183) at 1/500 dilution.
The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) (high pressure) for 2 minutes. The tissues were blocked in 10% negative goat serum for 1 hour at room temperature, washed with PBS, and then probed with the primary antibody (HA610183, green) at 1/500 dilution overnight at 4 ℃, washed with PBS. Goat Anti-Mouse IgG H&L (iFluor™ 488, HA1125) was used as the secondary antibody at 1/1,000 dilution. Nuclei were counterstained with DAPI (blue). -
Immunofluorescence analysis of paraffin-embedded BrdU treated mouse embryo tissue labeling BrdU with Mouse anti-BrdU antibody (HA610183) at 1/500 dilution.
The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) (high pressure) for 2 minutes. The tissues were blocked in 10% negative goat serum for 1 hour at room temperature, washed with PBS, and then probed with the primary antibody (HA610183, green) at 1/500 dilution overnight at 4 ℃, washed with PBS. Goat Anti-Mouse IgG H&L (iFluor™ 488, HA1125) was used as the secondary antibody at 1/1,000 dilution. Nuclei were counterstained with DAPI (blue). -
Immunocytochemistry analysis of BrdU/EdU treated NIH/3T3 cells labeling BrdU with Mouse anti-BrdU antibody (HA610183) at 1/250 dilution.
Cells were fixed in 4% paraformaldehyde for 20 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 5 minutes at room temperature, then blocked with 1% BSA in 10% negative goat serum for 1 hour at room temperature. Cells were then incubated with Mouse anti-BrdU antibody (HA610183) at 1/250 dilution in 1% BSA in PBST overnight at 4 ℃. Goat Anti-Mouse IgG H&L (iFluor™ 488, HA1125) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. Nuclear DNA was labelled in blue with DAPI.
beta Tubulin (ET1602-4, red) was stained at 1/100 dilution overnight at +4℃. Goat Anti-Rabbit IgG H&L (iFluor™ 594, HA1122) were used as the secondary antibody at 1/1,000 dilution. -
Dot plot showing BrdU treated NIH/3T3 cells stained with HA610183. Cells were incubated with 10 µM BrdU for 30 minutes prior to being harvested, washed twice in 1x PBS and fixed in 70% ethanol at 4℃ for 30 minutes. Once fixed, pellets were acid denatured with 2M HCl for 30 minutes at room temperature and then neutralised with borate buffer (0.1M, pH8.5) for 15 minutes.
Samples were washed and incubated in 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (HA610183, 1µg/ml) for 30 min at room temperature. The secondary antibody used was iFluor™ 488 conjugate-Goat anti-Mouse IgG (HA1125) at 1/1,000 dilution for 30 minutes at room temperature.
PI was added to cells 15 min prior to data acquisition.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"